In June of 2024, the United States (US) Food and Drug Administration (FDA) approved Cepheid’s GeneXpert (XpertⓇHCV) for Point of Care (POC) hepatitis C (HCV) diagnostic testing, the first of its kind for HCV in the US.  The test is CLIA (Clinical Laboratory Improvement Amendment) waived, meaning the instrument is simple to use and with … Continue reading New Hepatitis C Testing Technology Provides Diagnosis in One Hour